Astellas Pharma Inc. Stock
€10.86
Your prediction
Astellas Pharma Inc. Stock
Pros and Cons of Astellas Pharma Inc. in the next few years
Pros
Cons
Performance of Astellas Pharma Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astellas Pharma Inc. | -1.680% | -3.915% | 5.291% | -21.079% | 1.844% | -24.194% | -14.047% |
| Santen Pharmaceutical Corp Ltd. | -0.920% | -2.703% | -3.571% | 22.727% | 21.348% | -14.286% | -31.350% |
| Chugai Pharmaceutical Co Ltd | -0.750% | -2.810% | 1.021% | 49.789% | 25.858% | 31.215% | - |
| Kyowa Hakko Kirin Co. Ltd. | -1.980% | -2.941% | 5.882% | 18.563% | 33.784% | -37.342% | 13.233% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Examining the financials of Astellas Pharma (US symbol: ALPMF) sheds light on a company operating in a highly competitive pharmaceuticals sector. The numbers speak volumes about its financial health, capital structure, and operational efficiency. Astellas Pharma has demonstrated a mix of robust revenue streams, investment in research and development, and a notably consistent dividend payment strategy, although it contends with challenges related to profit margins and debt levels.
*Pros: *
Strong Revenue Base: The reported revenue for the most recent fiscal year stands at approximately JPY 1.603 trillion, signaling a solid demand for Astellas Pharma's products. The quarterly revenue growth year-over-year at 17% indicates that the company is not simply maintaining its market position but actually expanding. Consistent revenue generation plays a crucial role in sustaining operations and providing cash flows for further investments.